Shots:
- Bayer to support the development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate, CVnCoV and will contribute its expertise and established infrastructure in numerous area
- Curevac will be the MAH for the product while Bayer will support CureVac with country operations within the EU and additional markets. Additionally, Bayer has an option to MAH outside the EU
- The companies plan to combine their strengths for CureVac to be in a position to supply hundreds of millions of CVnCoV doses across the globe
Click here to read full press release/ article | Ref: Bayer | Image: GMPNews
The post Bayer Collaborates with CureVac for CVnCoV Against COVID-19 first appeared on PharmaShots.